CJC-1295 (No-DAC) and Ipamorelin are supplied together as a lyophilized blend because they are two of the most frequently co-studied peptides in growth-hormone-axis research — not because they are chemically related, but because their mechanisms sit on complementary branches of the same signaling pathway.
What each peptide is
CJC-1295 is a stability-enhanced synthetic analog of growth-hormone-releasing hormone (GHRH), acting on the GHRH receptor of pituitary somatotrophs. The No-DAC designation specifies that this version lacks the albumin-binding Drug Affinity Complex used in some CJC-1295 formulations to extend circulating half-life, giving it a shorter, more time-bounded activity profile. Ipamorelin is a five-amino-acid synthetic peptide that acts on a separate receptor — the growth-hormone secretagogue (ghrelin) receptor — and is notable in research literature for its high selectivity, showing little cross-reactivity with other pituitary hormone pathways.
Why they're studied as a pair
Because the two peptides engage different receptors converging on the same output — pituitary growth-hormone release — combining them lets researchers ask whether dual-pathway activation behaves additively, synergistically, or simply redundantly compared to either receptor alone. That question sits at the center of most published interest in this specific pairing, and it is explored in more depth in CJC-1295 vs. Ipamorelin.
How the research is conducted
Work in this space spans in-vitro receptor and cell-signaling assays through to animal-model studies of the intact growth-hormone axis, with all concentrations and exposure protocols determined entirely by the study design rather than any human-use reference. This is laboratory research aimed at characterizing signaling biology, not a therapeutic or performance application.
How the blend is supplied and verified
The product is supplied as a lyophilized powder containing both peptides, reconstituted with bacteriostatic water prior to use in an experimental protocol. Each production batch carries its own Certificate of Analysis documenting purity and identity of both components, verified independently by chromatography and mass spectrometry rather than taken on the label's word alone. Common practical questions about handling, testing, and sourcing the blend are addressed together in the CJC-1295 & Ipamorelin research FAQ.
Where this research fits in the broader literature
Growth-hormone-axis signaling is a well-established area of endocrinology research, and GHRH analogs together with secretagogues represent one specific experimental approach within that broader field — distinct from, for example, research into growth hormone itself or into IGF-1 analogs directly. The CJC-1295/Ipamorelin pairing is of interest specifically because it allows two different points of pharmacological entry into the same axis to be studied side by side, rather than requiring separate experimental setups for each mechanism.
Scope of this overview
This article summarizes the pairing at a high level; more detailed treatment of the underlying receptor mechanisms, the discovery history of each peptide, supporting preclinical data, and analytical verification methods are each covered in their own dedicated articles linked throughout this research library.
Product page: CJC-1295 (No-DAC) & Ipamorelin research blend.
Research Use Only. Supplied strictly for laboratory research and development — not for human or veterinary use, consumption, or any therapeutic or diagnostic purpose. This article is research education, not usage guidance.